We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Life Sciences

  • April 24, 2019

    J&J, Colgate's Talc Cancer Link 'Makes Sense,' Jury Told

    An epidemiologist hired by a dying woman who contends that Johnson & Johnson and Colgate-Palmolive's talcum products contained cancer-causing asbestos told a California jury on Wednesday it "makes sense" that asbestos exposure in the woman's teens would cause her mesothelioma decades later.

  • April 24, 2019

    Monsanto Appeals $78.5M Loss In First Roundup Trial

    Monsanto asked a California appeals court Tuesday to reverse a $78.5 million verdict awarded to a school groundskeeper who claimed Roundup weedkiller caused his lymphoma in the first landmark trial over the herbicide’s alleged cancer risks.

  • April 24, 2019

    FTC Accuses Electronic Prescription Co. Of Monopolization

    The Federal Trade Commission said Wednesday that it has sued Surescripts in D.C. federal court over allegations that the company uses contract terms and other tactics to illegally maintain its monopoly over electronic prescription services.

  • April 24, 2019

    After 10 Days Of Jury Silence, Insys Exec Asks To Go Home

    One of the five former Insys Therapeutics Inc. executives on trial for conspiring to bribe doctors to prescribe an opioid spray to patients who did not need it is asking the court to let her await her verdict from home as the jury enters its 11th day of deliberation.

  • April 24, 2019

    Philly Jury Slams J&J With $120M Award In Mesh Injury Case

    A Philadelphia jury hammered a Johnson & Johnson unit with $120 million in damages Wednesday after agreeing that a negligently designed pelvic mesh implant left a woman all but incontinent and suffering from chronic pain that prevented her from having sex.

  • April 24, 2019

    Investor Sues Boston Scientific Over FDA's Mesh Product Pull

    An investor sued Boston Scientific on Wednesday over the 7.7% drop in share price that followed the U.S. Food and Drug Administration's decision last week to pull the company's surgical mesh products from the U.S. market.

  • April 24, 2019

    FDA Urged To Crack Down On Anti-Smoking Supplements

    A food and health watchdog group has urged the U.S. Food and Drug Administration to crack down on certain dietary supplements that have been touted as help for smokers trying to quit but haven't undergone FDA scrutiny for effectiveness or safety. 

  • April 24, 2019

    Gene Therapy Co. Hit With Suit Over $877M Sale To Biogen

    A shareholder suit filed Tuesday in Boston federal court accuses London-based gene therapy developer Nightstar Therapeutics of leaving out key information in a regulatory filing about Biogen's plan to buy the company for $877 million, and asks a judge to delay a vote on the deal.

  • April 23, 2019

    Drug Lobby Says Athena Ruling May Zap Biotech Funding

    Biotech and pharmaceutical industry groups urged the full Federal Circuit on Monday to rethink a February ruling that nixed Athena Diagnostics' patent on an autoimmune disease testing method, saying the ruling threatens U.S. leadership in the diagnostic industry and other biotech sectors.

  • April 23, 2019

    Colgate Tells Jury In Talc Cancer Trial Its Mines Asbestos-Free

    An attorney for Colgate-Palmolive told a California jury Tuesday that its former talc product Cashmere Bouquet was sourced from asbestos-free mines and had nothing to do with a 61-year-old woman's mesothelioma, which she claims was caused by Colgate and Johnson & Johnson talc products. 

  • April 23, 2019

    What Drove DOJ's 1st Opioid Distributor Charges?

    The U.S. Department of Justice’s first felony charges accusing a drug distributor of fueling the opioid crisis involve familiar allegations of reckless painkiller sales that until now have been punished with civil penalties. But the accusations are also backed up by direct accounts of C-suite complicity, one of several factors that likely tipped the case into criminal waters.

  • April 23, 2019

    Amazon Gets Customer's Walker Injury Suit Trimmed

    Amazon notched a partial win Tuesday in a suit alleging a man was gravely injured by a faulty walker he purchased through the site, after a South Carolina federal court tossed two claims against the e-commerce giant and left two others hanging by a thread.

  • April 23, 2019

    Allergan Drug Buyers Take One Last Shot At Class Cert.

    Purchasers of Allergan's ulcerative colitis drug lodged a last-ditch effort for class certification in their antitrust suit, asking a Massachusetts federal judge Monday to reconsider denying them a chance to rework their bid after an appellate court rejected an earlier iteration.

  • April 23, 2019

    Big Biz Universally Beefing Up Compliance Units, KPMG Finds

    Big companies and other organizations across a variety of industries are boosting their ethics and compliance efforts, particularly in internal investigations, according to a new report from KPMG LLP.

  • April 23, 2019

    Synergy Pharmaceuticals Wins Ch. 11 Plan Approval

    Synergy Pharmaceuticals Inc. received court approval Tuesday to wind down in Chapter 11 under a bankruptcy plan that provides creditors with recoveries from a $195 million sale of the company's drug treatments to Bausch Health Cos. Inc., overcoming challenges from the federal government's bankruptcy case watchdog.

  • April 23, 2019

    J&J, Bausch Reach Talc Litigation Deal

    Bausch Health Cos. Inc. on Tuesday said that Johnson & Johnson has agreed to cover the costs of litigation over a "Shower to Shower" talc powder product that Bausch acquired in 2012.

  • April 23, 2019

    Cooley-Led Biotech Nixes IPO, Scores $142M Funding Round

    Cancer-focused biotechnology firm Poseida Therapeutics Inc. has decided to put plans for an initial public offering on hold, with the Cooley LLP-guided company instead picking up $142 million in a funding round led by pharmaceutical giant Novartis.

  • April 23, 2019

    Ex-Aveo CFO Says Securities Fraud Verdict Should Be Tossed

    The former chief financial officer of Aveo Pharmaceuticals asked a Massachusetts federal judge on Monday to erase the verdict against him for civil securities violations, saying it was based on a misreading of the law.

  • April 23, 2019

    Pet Medicine Cos.’ Suit To Block Rivals’ Tie-Up Tossed

    A California federal judge has thrown out pet medicine distributors' renewed challenge to the merger of two rivals, calling it too much like an earlier version that she said failed to make an antitrust case.

  • April 23, 2019

    Ex-Shkreli Atty Splitting Hairs Over 'Duty,' Gov't Says

    Prosecutors sought to preserve the conviction of Martin Shkreli's former attorney Evan Greebel on Monday, telling the Second Circuit that his claim that jury instructions used the wrong definition of a lawyer's "duty" was an attempt to draw a "fine-to-nonexistent line" that made no difference at his trial.

Expert Analysis

  • Rebuttal

    Jury Trials, Though In Decline, Are Well Worth Preserving

    Author Photo

    In a recent Law360 guest article, the author applauded the disappearance of jury trials as an inefficient, costly mechanism, but in doing so he overlooked the greater value of jury trials for our justice system, says Stephen Susman, executive director of the Civil Jury Project at NYU School of Law.

  • A Broader View Of The US Supreme Court Bar

    Author Photo

    During the past 15 years, three widely read articles bolstered by starstruck media have promulgated the incorrect perception — sorely in need of revision — that the U.S. Supreme Court bar is limited to a handful of elite lawyers, says Lawrence Ebner of Capital Appellate Advocacy.

  • Inside DOJ's Recent Charitable Copay Foundation Settlements

    Author Photo

    On April 4, the U.S. Department of Justice announced three settlements of False Claims Act cases, offering a glimpse into the ways the DOJ believes pharmaceutical companies have used charitable copay foundations to cover copays of government health program beneficiaries, circumvent anti-kickback laws and artificially bolster high drug prices, say attorneys with Skadden.

  • New USPTO Guidance May Help Diagnostics Patents

    Author Photo

    While Federal Circuit decisions have created a patenting barrier for diagnostics and personalized medicine claims, the U.S. Patent and Trademark Office's revised patent subject matter eligibility guidance may allow for these patents to make a comeback, say attorneys with Morris Manning.

  • In Virtual Teams For Mass Torts, The 'Law Team' Is Critical

    Author Photo

    A critical component of any virtual law team assembled for mass tort litigation is a dedicated "law team," which tackles the legal strategy and drafts the many necessary pleadings, motions and other submissions, say attorneys at Pepper Hamilton and Faegre.

  • Takeaways From DOJ Action Against Telemedicine Fraud

    Author Photo

    Recently unsealed indictments from the U.S. Department of Justice make clear that telemedicine will continue to be an enforcement focus at a time when telemedicine is expanding, and should remind providers to focus on compliance obligations, say Edgar Bueno and Matthew Wilmot of Morris Manning.

  • Answers To AI Patent Questions May Be Found In Biotech

    Author Photo

    In patenting innovations involving artificial intelligence, there is uncertainty on issues like inventorship, adequacy of disclosure, assessment of nonobviousness, and patent eligibility. The field of biotechnology once faced similar challenges, say Enrica Bruno and Brian Cash of Steinfl & Bruno.

  • 5 Tips For Lawyers Entering The Cannabis Industry

    Author Photo

    As the cannabis industry continues to grow, it will need more legal professionals to help navigate the turbulent business landscape, but lawyers should understand the industry's unique limitations and characteristics before diving in, says Sabas Carrillo of consulting firm Adnant.

  • Opinion

    Jury Trials Are In Decline For Good Reason

    Author Photo

    A recent Law360 article reported on federal judges bemoaning jury trials' nationwide decline, but these laments are unfounded as jury trials have been replaced by better alternatives, says J.B. Heaton of J.B. Heaton Research.

  • Genetic Testing Is On FTC's Radar

    Author Photo

    Recent Federal Trade Commission blog posts suggest potentially increased interest in the genetic testing arena, and the vague recommendations they offer may give the FTC broad latitude from an enforcement perspective, say attorneys at Moses & Singer.